• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzylethers

The Synthesis, Properties, and Applications of 3-[(Benzyloxy)methyl]Aniline (CAS No. 117401-77-1) in Chemical and Pharmaceutical Research

3-[(Benzyloxy)methyl]Aniline, identified by CAS No. 117401-77-1, is a structurally complex aromatic amine featuring a benzyloxymethyl group attached to the meta position of an anilino core. This compound represents a critical intermediate in organic synthesis due to its versatile reactivity profile and potential applications in drug discovery pipelines. Recent advancements in synthetic methodologies have positioned this compound as a focal point for researchers exploring bioactive molecules with tailored pharmacokinetic properties.

The molecular architecture of N-(benzyloxymethyl)aniline combines the electron-donating character of the anilino moiety with the steric bulk of the benzyl ether substituent. This unique balance enables it to act as a bifunctional building block in multistep syntheses. A groundbreaking study published in Chemical Communications (2023) demonstrated its utility as a precursor for constructing chiral oxazolidinone scaffolds through asymmetric organocatalytic reactions—a development that significantly reduces synthetic steps compared to traditional methods.

In pharmaceutical research, this compound has gained attention for its role in developing anti-inflammatory agents targeting COX isoforms. A 2022 collaborative study between MIT and Pfizer revealed that derivatives incorporating the benzyloxymethyl group exhibit selective inhibition of COX-2 with IC?? values as low as 5 nM while sparing off-target interactions with other cyclooxygenase isoforms. The meta positioning of this substituent was shown to optimize hydrophobic interactions within the enzyme's active site through X-ray crystallography analysis.

Synthetic chemists have leveraged the nucleophilic aromatic substitution potential of this compound's anilino group in palladium-catalyzed cross-coupling reactions under mild conditions (JACS Au, 2023). By utilizing ligand-accelerated protocols at ambient temperature, researchers achieved >95% yields for C-N bond formations with aryl halides—a significant improvement over conventional Suzuki-Miyaura conditions requiring elevated pressures.

Bioisosteric replacements incorporating the benzyloxymethyl motif have also been explored in antiviral drug design. A recent preprint on bioRxiv (August 2024) describes its application as a bioisostere for methoxy groups in HIV protease inhibitors, demonstrating enhanced metabolic stability while maintaining nanomolar potency against wild-type and drug-resistant viral strains through computational docking studies.

The physicochemical properties of this compound—specifically its solubility profile (log P = 3.8) and absorption characteristics—align well with modern drug delivery requirements outlined by FDA guidelines for orally administered drugs (JPC-B, 2024). Solid-state NMR analysis revealed polymorphic forms with distinct hydrogen bonding networks that influence dissolution rates—a critical consideration for formulation scientists optimizing bioavailability.

Ongoing investigations are exploring its use as a chiral auxiliary in asymmetric epoxidation processes using novel transition metal catalysts (Nat Catalysis Highlights, Q3 2024). These systems achieve enantioselectivities exceeding 98% ee under solvent-free conditions, representing a major step toward sustainable synthesis practices aligned with green chemistry principles.

In preclinical toxicology studies conducted by the European Medicines Agency (EMA), derivatives containing this structural motif showed favorable safety profiles compared to older generation compounds when tested across multiple species models (Toxicol Sci Advance Access Dec 2023). The absence of genotoxic effects up to doses exceeding therapeutic levels by three orders of magnitude underscores its potential for clinical development programs targeting chronic inflammatory conditions.

The synthesis pathway optimization continues to be an active research area with recent reports detailing microwave-assisted protocols achieving sub-hour reaction times at reduced catalyst loadings (Greener Synth Methods Journal, May 2024). This method reduces waste generation by over 65% compared to conventional reflux methods while maintaining product purity above analytical grade standards (HPLC >99%).

Cross-disciplinary studies combining computational modeling and experimental validation have illuminated novel applications for this compound's electronic properties in supramolecular chemistry (J Am Chem Soc Perspective Article July 2024). Its ability to form host-guest complexes with cyclodextrins has been harnessed to create stimuli-responsive drug delivery systems capable of pH-triggered release mechanisms—a breakthrough validated through live animal biodistribution studies.

In conclusion, CAS No. 117401-77-1-designated 3-(benzyloxymethyl)aniline stands at the intersection of cutting-edge synthetic strategies and translational biomedical research. Its structural features enable multifunctional applications ranging from precision medicinal chemistry to advanced material science constructs, making it an indispensable tool for addressing current challenges across diverse scientific domains.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)